Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $46.30B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: VTR stock price vs ALNY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Implied fair value · at VTR's multiple
Needs VTR P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VTR FY 2025 (ended Dec 31, 2025) · ALNY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 78% equity / 22% debt · EV / Revenue 10.04x · EV / EBITDA 39.88x
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
VTR carries the larger enterprise value at $58.57B against $38.07B; VTR trades on the lower EV / Revenue multiple (10.04x vs 10.25x); VTR on the lower EV / EBITDA (39.88x vs 63.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Ventas, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.04x
5.22x
Net debt / EBITDA
Leverage against operating earnings
8.35x
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
$741.07M
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WELLTOWER INC.
VTR vs WELL
Sabra Health Care REIT, Inc.
VTR vs SBRA
NATIONAL HEALTH INVESTORS INC
VTR vs NHI
OMEGA HEALTHCARE INVESTORS INC
VTR vs OHI
Moderna, Inc.
VTR vs MRNA
Sarepta Therapeutics, Inc.
VTR vs SRPT
VERTEX PHARMACEUTICALS INC / MA
VTR vs VRTX
BioNTech SE
VTR vs BNTX
ACADIA PHARMACEUTICALS INC
VTR vs ACAD
$13.01B
$4.12B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
